The global cephalosporin market size was valued at USD 15.94 billion in 2024 and is expected to reach USD 20.36 billion by 2032, at a CAGR of 3.10% during the forecast period
The market growth is largely fueled by the increasing prevalence of bacterial infections and the rising demand for broad-spectrum antibiotics, particularly in developing regions with inadequate sanitation and healthcare infrastructure. The cephalosporin class of antibiotics is widely prescribed due to its effectiveness, safety profile, and availability in multiple generations, making it a versatile treatment option for various infections including respiratory tract infections, skin infections, and urinary tract infections
Furthermore, growing antibiotic resistance is prompting healthcare providers to adopt newer-generation cephalosporins that offer enhanced efficacy against multidrug-resistant strains. These emerging therapeutic needs, along with improved access to healthcare services and the expansion of hospital infrastructures globally, are accelerating the uptake of cephalosporin-based treatments, thereby significantly boosting the market’s growth trajectory